

18.	<p><b>*Main outcome(s)</b></p> <p>Give the pre-specified main outcomes of the U-REACH project, including details of how the outcomes are defined / measured, and when these measurement are made, if these are part of the inclusion criteria. If no specific restriction is anticipated, please try to expose the general categorization of outcomes you plan to make.</p>
	<p><b>Primary Outcomes</b></p> <p><b>1. Core ADHD Symptoms</b></p> <ul style="list-style-type: none"> <li>Combined ADHD symptoms (inattentive + hyperactive/impulsive), rated by teachers, clinicians, parents/caregivers, or self-reported</li> </ul> <p><b>2. Acceptability and Tolerability</b></p> <ul style="list-style-type: none"> <li>Acceptability: all-cause discontinuation</li> <li>Tolerability: discontinuation due to adverse events</li> </ul> <p>Note: The core ADHD symptoms will be analyzed separately (when possible) depending on the timing of the measure: at post-test (closest 12 weeks), and, when available, closest to 26- or 52-weeks follow-up.</p>
19.	<p><b>*Additional outcome(s)</b></p> <p>List the pre-specified additional outcomes of the U-REACH project, with a similar level of detail to that required for main outcomes. Where there are no additional outcomes please state 'None' or 'Not applicable'.</p>
	<p><b>Secondary Outcomes</b></p> <p><b>1. Functional Outcomes</b></p> <ul style="list-style-type: none"> <li>Academic/job performance</li> <li>Clinical Global Impression (CGI) rated by clinicians or parents/caregivers</li> <li>Social-communication skills</li> <li>Driving performance</li> <li>Executive functioning</li> </ul> <p><b>2. Comorbid Psychopathology</b></p> <ul style="list-style-type: none"> <li>Conduct Disorder symptoms</li> <li>Oppositional Defiant Disorder symptoms</li> <li>Depressive disorder symptoms</li> <li>Manic symptoms</li> <li>Anxiety symptoms</li> <li>Learning disorder symptoms</li> <li>Tics/Tourette's disorder symptoms</li> <li>Emotional dysregulation</li> <li>Substance use disorder symptoms and behaviors</li> <li>Suicidal ideation/behavior</li> </ul> <p><b>3. Quality of Life</b></p> <ul style="list-style-type: none"> <li>Quality of life (patients)</li> <li>Quality of life (caregivers)</li> </ul> <p><b>4. Safety</b></p> <ul style="list-style-type: none"> <li>Specific adverse events: decreased appetite and sleep problems</li> </ul> <p>Note: All these outcomes will be analyzed separately (when possible) depending on the timing of the measure: at post-test (closest 12 weeks), and, when available, closest to 26- or 52-weeks follow-up.</p>

